25 results about "Brown adipose tissue" patented technology

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The invention discloses a central obesity early warning method and system based on BDNF dynamic monitoring, and relates to the field of dynamic monitoring of brain-derived neurotrophic factors.The method comprises the steps that the weight, the body length, the body temperature and the food intake of an experimental subject are obtained, fasting blood glucose and blood fat are detected through caudal vein blood sampling, a standardized physiological index data set is formed, and the standard physiological index data set is stored in a database; the method comprises the following steps: carrying out anatomical sampling on hypothalamus tissues, scapular brown adipose and perirenal adipose, and carrying out Western Blot detection to obtain the BDNF expression quantity of the hypothalamus tissues, the BDNF expression quantity of the scapular brown adipose tissues and the BDNF expression quantity of the perirenal adipose tissues; and acquiring the BDNF concentration time sequence data of the hypothalamus extracellular fluid through the implanted microdialysis module. According to the method, dynamic continuous monitoring of hypothalamic BDNF secretion is achieved through the implanted microdialysis technology, the rhythm disorder degree is quantified by calculating the sample entropy value, the limitation of a traditional static detection method is broken through, and early metabolic regulation abnormity can be captured more sensitively.

Light is fundamental for biological life, with most mammals possessing light-sensing photoreceptors in various organs. Opsin3 is highly expressed in adipose tissue which has extensive communication with other organs, particularly with the brain through the sympathetic nervous system (SNS). Our study reveals a new light-triggered crosstalk between adipose tissue and the hypothalamus. Direct blue-light exposure to subcutaneous white fat improves high-fat diet-induced metabolic abnormalities in an Opsin3-dependent manner. Metabolomic analysis shows that blue light increases circulating levels of histidine, which activates histaminergic neurons in the hypothalamus and stimulates brown adipose tissue (BAT) via SNS. Blocking central actions of histidine and denervating peripheral BAT blunts the effects of blue light. Human white adipocytes respond to direct blue light stimulation in a cell-autonomous manner, highlighting the translational relevance of this pathway. Together, these data demonstrate a light-responsive metabolic circuit involving adipose-hypothalamus communication, offering a potential strategy to alleviate obesity-induced metabolic abnormalities.

Among the various aspects of the present disclosure is the provision of methods for the treatment of type 1 diabetes by administering a brown adipose tissue (BAT)-secreted factor.

The invention discloses a fruit and vegetable fiber capable of improving GLP1 in vivo, which is prepared by the following steps: soaking peels of citrus fruits with hot water, removing white pulp layers, washing with water, and draining; grinding the fruit peels, inoculating aspergillus niger and plant lactobacillus, fermenting and sterilizing to obtain fermented fruit and vegetable fibers; performing ultrasonic treatment, adding water, adding xylanase and cellulase, performing enzymolysis, and performing enzyme deactivation to obtain enzymolysis fruit and vegetable fiber liquid; homogenizing, passing through an ultrafiltration membrane, intercepting filtrate, and spray-drying to obtain insoluble fibers; collecting permeate liquid, passing through a nanofiltration membrane, intercepting filtrate, and freeze-drying to obtain soluble fibers; and compounding the insoluble fiber part and the soluble fiber part to obtain the fruit and vegetable fiber. The invention further discloses application of the fruit and vegetable fibers in sugar control and weight reduction. The traditional Chinese medicine composition can effectively enhance satiety, inhibit excessive accumulation of white adipose tissues, activate a heat production function of brown adipose tissues, regulate body fat balance, activate a GLP-1 signal channel, inhibit appetite center and improve glycolipid metabolism.

The invention discloses an application of Pantoea ananatis, and relates to the technical field of microorganisms. Aiming at the defects of the existing obesity intervention means, the invention provides a brand-new solution: Pantoea anatitis adapted to a high-altitude environment is used as a core functional strain, through an intestinal flora driving mechanism, the expression of UCP1 protein in brown adipose tissue (BAT) is activated, the heat production function of the BAT is enhanced, and meanwhile, the storage of white adipose tissue (WAT) and the level of liver triglyceride (TG) are reduced; the weight-losing effect is realized. The strain can play a role through an'intestinal flora-BAT 'axis without cold exposure, has no obvious influence on liver functions, and is excellent in safety. The invention discloses a flora-mediated non-cold-dependent BAT activation way for the first time, can be used for preparing products such as weight-reducing medicines and health-care foods, has the advantages of mechanism innovation, exact effect and wide application, and provides a new technical choice for obesity intervention.

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

The inventors showed that intravenous administration of the small extracellular vesicles (sEVs) loaded with a plasmid encoding a dominant-negative mutant of NLRP3 under the control of the SF1 promoter (SF1-NLRP3-DN) slightly reduced body weight but did not modify food intake in atherosclerosis-prone ApoE knockout mice fed a high-fat diet, but induced an increase in brow adipose tissue (BAT) thermogenesis. Glucose tolerance was not affected after treatment with SF1-NLRP3-DN-loaded EVs. High-fat diet feeding induced an increase in the number of arrhythmias, as well as an increase in the onset of atrial fibrillation (AF) induced by transoesophageal stimulation, but also spontaneous arrhythmias that was not modified by the treatment with non-loaded EVs. Interestingly, EVs loaded with SF1-NLRP3-DN almost completely prevented both induced and spontaneous arrhythmias (conduction block) and AF. Finally, echocardiographic analyses showed that SF1-NLRP3-DN-loaded EVs did not induce any change in the structural and functional capacity of the heart. Accordingly, the present invention relates to the use of particles for the treatment of cardiac events associated with obesity.

This invention discloses an emergency product and method for hypothermia protection in low-temperature environments, belonging to the field of hypothermia protection and emergency care. This invention is the first to apply triiodothyronine (T3) to the preparation of an emergency product for hypothermia protection in low-temperature environments, fully utilizing T3's ability to rapidly increase heat production in tissues such as brown adipose tissue, thereby enhancing the body's active heat production capacity. Combining the physiological metabolic characteristics of the human body with the pharmacological properties of T3, this invention has achieved excellent results in animal experiments. On the one hand, T3 can maintain the core body temperature of hypothermic experimental animals at a higher level for a longer period, resulting in increased swimming time and extending the golden time for rescue. On the other hand, it can effectively improve the recovery of body temperature after rescue, significantly increasing the success rate of treatment. However, when using T4, which is considered more effective in conventional clinical settings, no significant improvement in these two aspects was observed, fully demonstrating the specificity and superiority of T3.

The invention discloses bifidobacterium adolescentis and application of the bifidobacterium adolescentis in fat reduction. The bifidobacterium adolescentis is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.31381. The bifidobacterium adolescentis has the effects of reducing the body fat rate, reducing weight, inhibiting the body weight rebound after weight loss, maintaining the weight loss effect, improving the blood fat and the like, promotes brown fat to produce heat and promotes white fat to be converted into brown fat, and meanwhile has high safety superior to that of weight-reducing drugs. In addition, when the medicine or food is used for treating and preventing obesity, the total cholesterol and total triglyceride levels are reduced, the liver function is improved, the pancreas health is maintained, the fat cell area is reduced, liver fat infiltration is reduced, the intestinal flora is regulated, and the inflammation level is reduced.

The invention relates to the technical field of health-care functional food, in particular to novel application of a composition. The composition provided by the invention is prepared from the following raw materials in parts by weight: 120 parts of lotus leaves, 30 parts of haws and 80 parts of mulberry leaves. The raw materials are mainly selected from medicinal and edible food materials and part of common nutritional food materials which are all natural plant raw materials. The applicant deeply studies the characteristics of the raw materials, carries out comprehensive and systematic in-vivo and in-vitro experimental verification respectively by screening and blending various food raw materials according to the two characteristics of preventing and reducing obesity of the product, and finally determines the composition of the optimized variety of the raw materials. The invention also relates to an application of the functional health-care food for preventing and reducing obesity and synchronously protecting intestinal barriers and liver tissues, and the functional health-care food is used for preventing and reducing obesity by inhibiting the whitening of brown fat, promoting the browning of white fat and enhancing the heat energy conversion of body lipid after being taken.

The application provides a brown fat recognition method and recognition device based on plain CT images, and solves the technical problem that the recognition cost and recognition accuracy of the existing brown fat recognition cannot be matched. The method comprises the following steps: establishing a tissue feature recognition model of brown fat by using the image features of the brown fat in the plain CT image resources; identifying the brown fat in the to-be-detected plain CT image according to the tissue feature recognition model, and quantifying the physical properties of the brown fat. The tissue feature recognition model is mainly trained or optimized by using low-cost plain CT image data, so that the brown fat and white fat can be effectively distinguished. The application provides a basic tool for target point recognition and tissue quantification, so as to explore how to activate the brown fat tissue in the human body through drugs, nutrition and other means, and to expect to find new strategies for treating obesity and diabetes.

To provide a novel method for obtaining brown adipose tissue by differentiating stem cells. [Solution] A method for producing brown adipose tissue, comprising a culture step of culturing a hydrogel containing stem cells and a cationic polymer in a medium containing 3,3',5-triiodo-L-thyronine and insulin, thereby inducing differentiation of the stem cells into brown adipose tissue.

The application discloses a kind of adipose tissue-derived mitochondrial-derived vesicles and its preparation method and application, belong to the field of biological medicine.The preparation method includes obtaining mouse adipose tissue, including at least one of interscapular brown adipose tissue, epididymal white adipose tissue, beige adipose tissue, in vitro cultured adipocyte;Mouse adipose tissue homogenate is removed by differential centrifugation Unbroken cell, nucleus, mitochondrial and organelle precipitate, the supernatant obtained is treated by trypsin and then ultracentrifuged, the precipitate is collected, washed, to obtain mitochondrial-derived vesicles, which are membrane-coated vesicles, with a particle size of 100-200 nm, enriched in mitochondrial membrane proteins and oxidative phosphorylation-related proteins, and proved by ischemic heart disease model that it can improve heart function, reduce the degree of ventricular remodeling in mice with ischemic heart disease and reduce the fibrosis area, for the preparation of drugs for preventing or treating ischemic heart disease, and has important clinical application value.

The invention discloses an application of succinyl sulfathiazole in preparation of a weight-reducing medicine. The protein expression of ACLY in ACLY knocked-down C3H10T1 / 2 cells and the protein expression of ACLY in brown adipose tissues can be increased, and a heat production key pathway AMPK / PGC1 alpha / UCP1 pathway in the brown adipose tissues can be activated, so that heat production is increased, and metabolic disorder caused by high-fat diet can be remarkably improved.

The invention discloses application of nolinoleic acid in preparation of a medicine for treating obesity, and belongs to the technical field of biological medicine. The molecular formula of the nolinoleic acid disclosed by the invention is C17H28O2. The nolinoleic acid plays a positive role in enhancing brown fat heat production and treating obesity, and animal model experiment verification shows that intervention of the nolinoleic acid reduces the weight of obese mice induced by high fat diet, improves the weight of brown fat tissues, improves sugar tolerance and insulin sensitivity, and can be used for treating obesity. And the brown fat heat production function phenotype and the overall metabolism level of mice are increased, which indicates that the nolinoleic acid has an enhancement effect on brown fat heat production and has a certain improvement effect on obesity. The research result of the invention provides a new treatment approach for obesity treatment.

The invention discloses a polypeptide and application thereof, and relates to the technical field of biology. The amino acid sequence of the polypeptide is shown as SEQ ID NO: 1. The polypeptide designed based on the precise binding site of the Gabp alpha and the Ppargamma comprises an aa164-189 amino acid sequence fragment of the Ppargamma, ARG168 and LYS184 sites can be specifically bound with ASP332 and GLN324 sites of the Gabp alpha respectively, a natural binding interface of the Gabp alpha and the Ppargamma can be competitively occupied, specific blocking of the interaction of the Gabp alpha and the Ppargamma is achieved, and the effect of inhibiting the Gabp alpha and the Ppargamma is achieved. Non-specific interference caused by interaction of other proteins is avoided, and a high-specificity tool is provided for targeted regulation of a brown adipose tissue related metabolic process.

The utility model relates to the technical field of phototherapy, in particular to a light-operated blood glucose eyeshade device and a light-operated blood glucose eyeshade system. The light-operated blood glucose eyeshade device comprises a middle shell, an LED lamp panel and a rear shell. The middle shell and the rear shell are arranged on the two sides of the LED lamp panel. A plurality of LED lamp beads are arranged on the side, close to the rear shell, of the LED lamp panel. And the LED lamp panel is connected with the rear shell. And the middle shell is connected with the rear shell and covers the LED lamp panel. After a user correctly wears the eyeshade, red light emitted by the eyeshade can irradiate human eyes; red light enters from a visual window, signals can be directly transmitted by activating photosensitive retinal ganglion cells (ipRGCs) (special photoreceptor cells) through optic nerves to a series of nerve nuclei of hypothalamus and medulla oblongata, finally, the red light acts on peripheral brown adipose tissue BAT through sympathetic nerves, the metabolic capacity of blood sugar can be affected, and therefore the sugar control effect is achieved. And when the embodiment is used for reducing blood sugar, the user only needs to wear the equipment, so that the method is easy to implement.

According to the human body brown adipose tissue characterization method and device and the metabolic function evaluation system, automatic processing and visual comparison of multi-wavelength opto-acoustic / ultrasonic images before and after activation of the brown adipose tissue are achieved, and the clinical practicability and the image processing efficiency are improved. The method comprises the following steps: (1) acquiring a multi-wavelength photoacoustic image and an ultrasonic image of a region of interest of a target subject before and after cold stimulation; (2) performing luminous flux correction on the multi-wavelength photoacoustic image; segmenting different organizational structures in the region of interest by using the ultrasonic image, and performing luminous flux compensation on the photoacoustic image; (3) performing spectral unmixing processing on the multi-wavelength photoacoustic image after luminous flux compensation to obtain distribution images of different tissue components; the different tissue components at least comprise brown fat; and (4) based on the distribution image, calculating photoacoustic signal characteristic parameters of brown fat under different wavelengths before and after cold stimulation, and / or concentration change information of other tissue components except the brown fat, and generating a characterization evaluation result.

A method for directing a change in cell state of white adipose tissue (WAT) which involve treating WAT cells with mRNA encapsulated inside lipid nanoparticles (LNPs). The mRNA encodes UCP1 or other proteins that may transition WAT to brown adipose tissue (BAT). The LNP may contain (C14-4:NCL:Cholesterol:PEG / Lipid Conjugate) at the molar ratio of (35:16:46.5:2.5), (50:10:38.5:1.5) or (56.5:10:31.8:1.7).

To provide an improved anti-myostatin therapeutic drug.SOLUTION: Provided is a pharmaceutical composition to be used in a method for treating the state of a muscle in a subject, where the pharmaceutical composition specifically binds to pro / latent type myostatin, contains antibody which inhibits release of mature myostatin or a fragment thereof, and the pharmaceutical composition causes two or more of (a) an increase in the amount of a muscle tissue and / or function in the subject; (b) a rise of the metabolic rate of the subject; (c) an increase in the insulin sensitivity of the subject; (d) a rise of the brown fat tissue level in the subject, and the like.SELECTED DRAWING: None

The present invention provides novel methods for promoting recruitment and activation of brown adipose tissues (BAT) or arousing browning of white adipose tissues (WAT) in a mammal, comprising administration to the mammal a composition comprising an effective amount of dihydroberberine or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof. The present invention also provides a composition comprising an effective amount of dihydroberberine or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof, for promoting recruitment and activation of brown adipose tissues (BAT) or arousing browning of white adipose tissues (WAT) in a mammal.

A method for directing a change in cell state of white adipose tissue (WAT) which involve treating WAT cells with mRNA encapsulated inside of a lipid nanoparticle (LNP). The mRNA encodes a sequence for synthesizing UCP1 or other proteins that may transition adipose tissue from WAT to brown adipose tissue (BAT). The LNP may contain (C14-4: NCL: Cholesterol: PEG / Lipid Conjugate) at the molar ratio of (35: 16: 46.5: 2.5), (50: 10: 38.5: 1.5) or (56.5: 10:31.8: 1.7).

Provided are an application of a GluN3B inhibitor in the preparation of a drug for preventing or treating obesity and related metabolic syndrome, and an application of the GluN3B inhibitor in the prevention and treatment of obesity. By means of using a high-fat diet (45% fat)-induced obesity model as a research subject, it has found that GluN3B gene knockout or knockdown can effectively inhibit the weight gain of mice. In vivo animal experiments show that the GluN3B gene knockout or knockdown can activate brown adipose tissue to significantly promote the energy consumption of mice, which is an important reason for the slowed weight gain of mice.

This invention provides the application of fuscin acid in the preparation of weight loss, lipid reduction, and metabolism improvement products, offering a new use for fuscin acid. It can effectively reduce subcutaneous fat weight, decrease the whitening degree of brown adipose tissue, reduce the size of adipocytes in visceral adipose tissue, improve the fatty liver phenotype, improve glucose tolerance, and reduce serum TG and TC levels, without affecting the weight of brown adipose tissue and muscle tissue, providing an effective solution for safe and effective weight loss using traditional Chinese medicine extracts.